Home Featured Page 16

Featured

Latest

Rethinking Addiction and Treatment Models: Is the Recovery Community Ready for Psychedelics?

Psychedelics Today Gifting Guide 2024

The Mystical Roots of Psychedelics: Exploring Dreams and the Liminal State

SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy

Pα+ Psychedelic Bulletin #183:

No NHS Coverage for Janssen’s Spravato: NICE Denies Re-Appraisal of Esketamine...

Natural Medicine Advisory Bulletin 11.6: June 14th Subcommittee: Problems with Products

Spirituality: An Essential Understanding for Psychedelic Integration

Self-Care, Destabilization, and the Holistic Nature of Psychedelics

Expanding Psychedelic Clinical Trials to LGBTQ+ Populations

An Inside Look at the FDA and Early Drug Development

In Conversation: Joanna Kempner, Author of “Psychedelic Outlaws: The Movement Revolutionizing...

Community, Group Process, and Co-Creation: How to Build a Successful Retreat

Pα+ Psychedelic Bulletin #164: Lykos Dominates News Cycle; EPIsoDE Trial Readout;...

Breaking: Lykos Therapeutics Moved to Patent MDMA In Late 2022, Filing...

1...151617...277 Page 16 of 277

Rethinking Addiction and Treatment Models: Is the Recovery Community Ready for...

Psychedelics Today Gifting Guide 2024

The Mystical Roots of Psychedelics: Exploring Dreams and the Liminal State

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Rethinking Addiction and Treatment Models: Is the Recovery Community Ready for Psychedelics?

Psychedelics Today Gifting Guide 2024

The Mystical Roots of Psychedelics: Exploring Dreams and the Liminal State

SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy

Pα+ Psychedelic Bulletin #183:

No NHS Coverage for Janssen’s Spravato: NICE Denies Re-Appraisal of Esketamine...

Natural Medicine Advisory Bulletin 11.6: June 14th Subcommittee: Problems with Products

Spirituality: An Essential Understanding for Psychedelic Integration

Self-Care, Destabilization, and the Holistic Nature of Psychedelics

Expanding Psychedelic Clinical Trials to LGBTQ+ Populations

An Inside Look at the FDA and Early Drug Development

In Conversation: Joanna Kempner, Author of “Psychedelic Outlaws: The Movement Revolutionizing...

Community, Group Process, and Co-Creation: How to Build a Successful Retreat

Pα+ Psychedelic Bulletin #164: Lykos Dominates News Cycle; EPIsoDE Trial Readout;...

Breaking: Lykos Therapeutics Moved to Patent MDMA In Late 2022, Filing...

EDITOR PICKS

Rethinking Addiction and Treatment Models: Is the Recovery Community Ready for...

Psychedelics Today Gifting Guide 2024

The Mystical Roots of Psychedelics: Exploring Dreams and the Liminal State

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY